Breaking News, Collaborations & Alliances

Jacobio Earns $20M AbbVie Milestone

Initiates Phase 1/2a trial of SHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Jacobio Pharmaceuticals dosed the first two patients in the Phase 1/2a clinical trial of SHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respectively, triggering a $20 million milestone payment from AbbVie.   This is the first milestone payment following the initial upfront fee of $45 million at the outset of the Jacobio/AbbVie’s collaboration. In May 2020, the companies entered an agreement to develop and commercialize SHP2 inhibitor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters